Lineage B.1.1.7

Memo Therapeutics AG Antibodies Against SARS-CoV-2 Show Efficacy Against British and South African Variant

Retrieved on:

Monday, May 17, 2021

Research, Medical Supplies, Infectious diseases, Genetics, Clinical trials, Biotechnology, General Health, Pharmaceutical, Health, Science, Medical specialties, Immunology, Branches of biology, Health, Variants of SARS-CoV-2, Zoonoses, COVID-19, Antibody, Lineage B.1.1.7

b'Memo Therapeutics AG (\xe2\x80\x9cMemo\xe2\x80\x9d), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).

Key Points:

b'Memo Therapeutics AG (\xe2\x80\x9cMemo\xe2\x80\x9d), an innovator in the field of antibody discovery and development, announced today that MTX-COVAB, its human-derived antibody against SARS-CoV-2, the virus that causes COVID-19, has shown efficacy against both the original virus as well as the UK variant (B.1.1.7).
Memo is now preparing MTX-COVAB for clinical evaluation.\nUsing its microfluidic, single-cell molecular cloning and screening technologies to enable antibody repertoire mining and antibody discovery, Memo can discover novel antibodies at unprecedented speed, efficiency and sensitivity derived from recovered patient samples.
This can be achieved in as little as 3 weeks from receiving the blood sample.\n\xe2\x80\x9cAddressing SARS-CoV-2 variants remains a global challenge and one that will remain.
Memo Therapeutics AG is a private company located in Bio-Technopark Zurich, Switzerland.\nView source version on businesswire.com: https://www.businesswire.com/news/home/20210517005220/en/\n'

Ocugen announces studies showing COVAXIN potentially effective against three key variants of SARS-CoV-2

Retrieved on:

Monday, May 3, 2021

Variants of SARS-CoV-2, SARS-CoV-2, BBV152, COVID-19 pandemic in India, Lineage B.1.617, COVID-19, Lineage B.1.1.7, Forward-looking statement, Articles

As previously disclosed, a study conducted by ICMR also suggested that COVAXIN was effective against the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617.

Key Points:

As previously disclosed, a study conducted by ICMR also suggested that COVAXIN was effective against the UK variant, B.1.1.7, as well as the Indian double mutant variant, B.1.617.
We continue to believe this vaccine is a critical tool to include in our national arsenal to fight this pandemic.
This information involves risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements.
Any forward-looking statements that we make in this press release speak only as of the date of this press release.

SARS-CoV-2 variants of concern pose a higher risk for hospitalisation and intensive care admission

Retrieved on:

Saturday, May 1, 2021

Variants of SARS-CoV-2, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Companies, Dutch East India Company, Trade, Economy, 501.V2 variant

A study coordinated by ECDC together with seven EU countries Cyprus, Estonia, Finland, Ireland, Italy, Luxembourg, and Portugal analysed data on the three VOC reported by the collaborating countries, and the research shows a higher risk for hospitalisation and intensive care admission.

Key Points:

A study coordinated by ECDC together with seven EU countries Cyprus, Estonia, Finland, Ireland, Italy, Luxembourg, and Portugal analysed data on the three VOC reported by the collaborating countries, and the research shows a higher risk for hospitalisation and intensive care admission.
The analysis of 19 995 VOC and 3 348 non-VOC cases suggests that the VOC pose a higher risk for developing severe diseases.
Compared to cases infected with a non-VOC virus, the risk for hospitalisation in B.1.1.7 cases was 1.7 times higher, while in B.1.351 it was 3.6 times higher and for P.1 it was 2.6 times higher.
This study also showed an increased risk of being admitted to intensive care by 2.3, 3.3 and 2.2 times higher for people infected by B.1.1.7, B.1.351 and P.1 respectively, compared to non-VOC cases.

Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic

Retrieved on:

Monday, April 12, 2021

Articles, Variants of SARS-CoV-2, Health, Global health, Pandemics, Zoonoses, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, 501.V2 variant, Virus, Variant of concern

The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.

Key Points:

The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.
"Seegene will continue to closely monitor developments on the virus variant front and provide additional variant tests to help contain the spread of the virus and put an end to the pandemic.
the so-called "UK variant" has proven to be not only more contagious but also deadlier, raising alarm across the world.
Seegene continues to set new standards in MDx providing new, cost-effective innovations.\n'

Seegene begins exporting its latest COVID-19 variant tests around the world to help contain spread of pandemic

Retrieved on:

Monday, April 12, 2021

Articles, Variants of SARS-CoV-2, Health, Occupational safety and health, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, COVID-19, 501.V2 variant, Pandemic, Variant of concern, COVID-20

The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.

Key Points:

The variant test can detect virus variants including B.1.1.7, B.1.351 and P.1.
"Seegene will continue to closely monitor developments on the virus variant front and provide additional variant tests to help contain the spread of the virus and put an end to the pandemic.
the so-called "UK variant" has proven to be not only more contagious but also deadlier, raising alarm across the world.
Seegene continues to set new standards in MDx providing new, cost-effective innovations.\nView original content to download multimedia: http://www.prnewswire.com/news-releases/seegene-begins-exporting-its-lat...\n'

Bold Therapeutics' BOLD-100 Effective In Vitro Against COVID-19 Variants

Retrieved on:

Friday, April 16, 2021

Drug discovery, Pharmaceutical industry, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Preclinical development, In vitro, In vivo, Antiviral drug, Health sciences, Life sciences, Biology

New in vitro research completed by Bold Therapeutics\' collaborators at the University of British Columbia and Western University showed that BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including the highly prevalent B.1.1.7 variant originally identified in the UK (see Figure 1).

Key Points:

New in vitro research completed by Bold Therapeutics\' collaborators at the University of British Columbia and Western University showed that BOLD-100 consistently reduced viral concentrations in multiple COVID-19 variants, including the highly prevalent B.1.1.7 variant originally identified in the UK (see Figure 1).
This work confirms and expands upon prior research demonstrating that BOLD-100 has strong antiviral activity against COVID-19 in a range of preclinical in vitro models.
Since that time, Bold Therapeutics has generated additional efficacy and safety data, including the aforementioned variant studies, and is currently completing in vivo studies of BOLD-100.
In parallel, Bold Therapeutics continues to enroll patients in its Phase 1b study of BOLD-100 in the treatment of advanced gastrointestinal cancers.

COVID-19 Antibody Tests For Variants Now Available Worldwide

Retrieved on:

Monday, March 29, 2021

Coronaviridae, Sarbecovirus, SARS-CoV-2, Variants of SARS-CoV-2, Zoonoses, Occupational safety and health, Atypical pneumonias, COVID-19, 501.V2 variant, Severe acute respiratory syndrome coronavirus, Lineage B.1.1.7, Lineage P.1

(MSD) today announced the commercial release of its V-PLEX Serology Panels for SARS-CoV-2 variants.The release includes panels that test for important variants spreading worldwide, including the B.1.1.7, B.1.351, and P1 variants, referred to in the news as the U.K., South African, and Brazilian variants, respectively.

Key Points:

(MSD) today announced the commercial release of its V-PLEX Serology Panels for SARS-CoV-2 variants.The release includes panels that test for important variants spreading worldwide, including the B.1.1.7, B.1.351, and P1 variants, referred to in the news as the U.K., South African, and Brazilian variants, respectively.
Variants of SARS-CoV-2 may evade immunity or increase transmission, increasing COVID-19 cases and potentially diminishing the impact of vaccines.MSD's new V-PLEX Serology Panels help scientists understand how SARS-CoV-2 variants respond to antibodies generated by vaccination or natural infection.
Jacob Wohlstadter, President and Chief Executive Officer, remarked, "The emergence of certain new SARS-CoV-2 variants presents a challenge to the worldwide effort to combat COVID-19.We are grateful to the many organizations studying and developing new vaccines for important variants.
"These new tests will accelerate the timelines for developing vaccines against variants," said James Wilbur, Chief Business Officer of MSD.

DGAP-News: Formycon's COVID-19 Drug FYB207 even more efficient against SARS-CoV-2 Mutant B.1.1.7

Retrieved on:

Thursday, March 25, 2021

Health sciences, Zoonoses, Health, Articles, Angiotensin-converting enzyme 2, Coronavirus, COVID-19, Lineage B.1.1.7, Virus

These show that FYB207 is even more efficient against the B.1.1.7 mutant of the virus, which is considered particularly infectious, than against earlier variants.

Key Points:

These show that FYB207 is even more efficient against the B.1.1.7 mutant of the virus, which is considered particularly infectious, than against earlier variants.
In addition, FYB207 can potentially be used with all coronaviruses that use ACE2 as a portal of entry.
The preclinical activities as well as the preparations for the entry into clinical trials with FYB207 are proceeding according to plan.
In addition, Formycon had a successful Scientific Advice Meeting with the Paul-Ehrlich-Institute and has already secured GMP manufacturing capacity for FYB207.

Article - Covid-19 variants: state of play and impact on vaccination in the EU

Retrieved on:

Wednesday, March 17, 2021

Health, Articles, SARS-CoV-2, Variants of SARS-CoV-2, Occupational safety and health, COVID-19 pandemic in the United Kingdom, Lineage B.1.1.7, Coronavirus disease, Vaccination, Vaccine, COVID-19 pandemic, 501.V2 variant

As part of Parliaments continued close monitoring of the EUs vaccination strategy, members of the environment and public health committee heard fromrepresentatives from the European Centre for Disease Prevention and Control, the European Medicines Agency and the World Health Organization on the efficacy of vaccines against mutations of the Covid-19 virus.

Key Points:

As part of Parliaments continued close monitoring of the EUs vaccination strategy, members of the environment and public health committee heard fromrepresentatives from the European Centre for Disease Prevention and Control, the European Medicines Agency and the World Health Organization on the efficacy of vaccines against mutations of the Covid-19 virus.
This was the latest in a string of hearings and events during which key players in the Covid-19 crisis are keeping MEPs updated on their work.
Three main variants in the EU
Dr Bruno Ciancio, head of surveillance at the European Centre for Disease Prevention and Control, said there are currently three main variants of concern in the EU: the UK variant, the South African variant and the Brazilian variant.
Given the current knowledge of the variants, he said the centre's models predict that the current measures and vaccination strategy rolled out by the EU will still be effective, but stressed the importance of countries keeping track of variants and their spread.

ImmunoPrecise Antibodies Announces Results from a Comprehensive Screening of 27 Proprietary Anti-SARS-CoV-2 Therapeutic Antibodies

Retrieved on:

Tuesday, March 16, 2021

Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical studies to reveal full interaction profiles against seventeen different SARS-CoV-2 variants.

Key Points:

Twenty-seven extensively characterized, proprietary, lead candidate antibodies have been generated and analyzed by ImmunoPrecise in its preclinical studies to reveal full interaction profiles against seventeen different SARS-CoV-2 variants.
Results of the screening also indicate that identified antibodies retain the ability to bind to emerging SARS-CoV-2 variants including U.K. (B.1.1.7 lineage), S. African (B.1.351 lineage) and Brazilian (P.1 lineage) strains.
Researchers studying SARS-CoV-2, the virus that causes COVID-19, have indicated that global variants are more transmissible than the original strain.
The forward-looking statements contained in this news release are made as of the date of this release and, accordingly, are subject to change after such date.